Drug Delivery

Oramed Pharmaceuticals discusses benefits of oral insulin versus insulin inhaler

Published in Health Business Week, January 12th, 2007

Oramed Pharmaceuticals, Inc. (ORMP; OJU) stressed the benefits of their oral insulin capsule in contrast to another popular insulin delivery system that is entering the market --the insulin inhaler.

Dr. Miriam Kidron, Oramed's chief technology officer, was asked to comment on the comparison of Oramed's insulin capsule versus an insulin inhaler. Dr. Kidron responded, "There is no comparison. The inhaler was designed in an effort to mimic the effects of subcutaneous insulin, which is not physiologically natural. Insulin should not be delivered directly into the bloodstream. Oramed's capsule provides a better physiological entry for insulin."

Kidron was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2007-01-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry